Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tharimmune Inc (THAR)

Tharimmune Inc (THAR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,125
  • Shares Outstanding, K 37,730
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,200 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.43
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.76

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.71 +57.56%
on 01/21/26
5.83 -26.76%
on 02/02/26
+1.26 (+41.86%)
since 01/12/26
3-Month
2.18 +95.83%
on 11/20/25
5.83 -26.76%
on 02/02/26
+1.05 (+32.61%)
since 11/12/25
52-Week
0.95 +348.53%
on 04/07/25
9.08 -52.97%
on 08/25/25
+2.38 (+125.93%)
since 02/12/25

Most Recent Stories

More News
Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer

Leadership Expansion Supports Execution of Canton Network Infrastructure Strategy

THAR : 4.22 (-2.99%)
Tharimmune Elects Jill Sommers and William Wiley to Board of Directors

New Directors Strengthen Governance as Company Advances Canton Network Infrastructure

THAR : 4.22 (-2.99%)
Tharimmune Announces Expanded Role as Super Validator on Canton Network

Advances Digital Asset Treasury Strategy Through Contributions to Canton Network

THAR : 4.22 (-2.99%)
Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional...

THAR : 4.22 (-2.99%)
Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering

NEW YORK , Jan. 20, 2026 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR), the first publicly traded company to leverage Canton Coin to support the Canton Network's ability to digitize traditional...

THAR : 4.22 (-2.99%)
Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network

Milestone Underscores Accelerating Institutional Adoption of Blockchain Technology and Aligns with Tharimmune's Canton Coin Treasury Strategy

THAR : 4.22 (-2.99%)
Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy

Former Clear Street Group CFO Strengthens Leadership Team Alongside Industry Veterans Mark Wendland and Mark Toomey

THAR : 4.22 (-2.99%)
Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids

RED BANK, N.J. , Nov. 13, 2025 /PRNewswire/ -- Tharimmune, Inc. (Nasdaq: THAR) ("Tharimmune" or the "Company"), a digital asset treasury company with a clinical-stage biotechnology function,...

THAR : 4.22 (-2.99%)
Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy

Led by DRW and Liberty City Ventures, Transaction Cements Tharimmune as First Public Company to Deliver Canton-Aligned DAT Strategy

THAR : 4.22 (-2.99%)
Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy

NEW YORK , Nov. 3, 2025 /PRNewswire/ -- Tharimmune, Inc. (NASDAQ: THAR) ("Tharimmune" or the "Company") today announced that it has entered into subscription agreements with certain institutional...

THAR : 4.22 (-2.99%)

Business Summary

Tharimmune Inc. is a biotechnology company. It involved in developing a portfolio of therapeutic candidates for rare immune, inflammatory and oncologic diseases. Tharimmune Inc., formerly known as Hillstream BioPharma Inc., is based in BRIDGEWATER, NJ.

See More

Key Turning Points

3rd Resistance Point 5.08
2nd Resistance Point 4.87
1st Resistance Point 4.61
Last Price 4.22
1st Support Level 4.14
2nd Support Level 3.93
3rd Support Level 3.67

See More

52-Week High 9.08
Fibonacci 61.8% 5.98
Fibonacci 50% 5.02
Last Price 4.22
Fibonacci 38.2% 4.06
52-Week Low 0.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar